Recommended Free Tools
There is no single new technology revolutionizing breast cancer care. The phrase can refer to 3D mammography used in screening, AI tools being studied or used for specific clinical tasks, imaging during surgery, or tests that guide treatment. Each works at a different point in care, and evidence that a tool detects more tumors does not, by itself, show that it saves more lives.
What technologies are changing breast cancer care?
Several distinct technologies are involved. Digital breast tomosynthesis (DBT), commonly called 3D mammography, is an imaging method used in screening. AI may assist with image interpretation or other defined tasks. Intraoperative imaging can help clinicians assess tissue during surgery. Biomarker testing can help match treatment to features of a diagnosed tumor.
As an Amazon Associate I earn from qualifying purchases.
These are not interchangeable tools, nor do they apply to every patient. Screening and treatment decisions depend on personal risk, medical history, diagnosis, tumor features and the clinical setting.
Free tools Windows power users keep installed
One-click scans. No signup required.
What is a 3D mammogram, and how does it compare with 2D?
DBT uses an X-ray source that moves through an arc, taking images from multiple angles. Software reconstructs them into thin slices through breast tissue. Instead of looking only at a single flattened image, the interpreting clinician can review tissue at different depths. This may help reduce the masking effect of overlapping tissue; the FDA says DBT devices may be helpful in evaluating dense breast tissue.
#1 Best Overall
| Question | 2D digital mammography | 3D mammography (DBT) |
|---|---|---|
| How images are made | Standard digital mammography images. | X-ray images are taken from multiple angles and reconstructed into slices. |
| Cancer detection evidence | Used as a standard screening method. | The National Cancer Institute (NCI) says DBT combined with standard mammography detects more tumors than standard mammography alone. |
| Whether it reduces deaths | Not a comparative outcome established by the cited NCI summary. | Whether DBT reduces breast cancer deaths compared with standard mammography remains unknown, according to NCI. |
More cancers found in screening is not the same outcome as fewer deaths. It also does not, by itself, establish whether additional detection includes cancers that would not have caused harm. The randomized TMIST study compares FDA-approved 2D digital mammography with 3D tomosynthesis and uses advanced breast cancer as a key outcome.
Who should consider 3D mammography?
The choice of screening method should be discussed with a clinician in light of personal risk, family and medical history, breast density, and local availability. The FDA notes that mammograms remain the primary screening method for finding breast cancer early. DBT is a clinical imaging exam, not an at-home test.
NCI reports that the U.S. Preventive Services Task Force recommends screening mammograms every two years for average-risk women ages 40–74. That schedule is not a universal plan: people with very high risk or relevant medical history may need different screening. Ask a clinician which schedule and test fit your circumstances.
Quick wins for a faster PC:
Repair Windows errors before they cause bigger problemsFix Now →Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →Does AI detect breast cancer?
AI is not one single test. Researchers are investigating its use in mammogram interpretation and early detection, including work on identifying people with ductal carcinoma in situ (DCIS) who may be at greater risk of progression. That research does not establish AI as a stand-alone replacement for radiologists or standard screening.
A specific example illustrates why the task and setting matter. The FDA’s Claire OCT System record lists a decision date of March 3, 2026. It combines real-time, volumetric 3D optical coherence tomography imaging with an AI/ML detection algorithm that marks focal areas suspicious for cancer. Its labeled role is to assist evaluation of margins in excised lumpectomy tissue during surgery for patients with biopsy-confirmed breast cancer, alongside other standard methods and physician interpretation.
Rank #2
- Used Book in Good Condition
That is an intraoperative aid after diagnosis—not a routine screening test or a substitute for a clinician’s judgment. FDA notes that the labeling displayed in its record was current at original approval and may not reflect later supplements; patients and clinicians should verify current labeling when considering the device.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.How do biomarkers affect treatment?
After diagnosis, tests for tumor features and biomarkers can help clinicians determine which treatments may be appropriate. Targeted therapies interfere with proteins that help tumors grow; testing can help identify patients more likely to benefit. Options vary with disease features such as HER2 status, hormone receptor status, or BRCA-associated disease.
Breast cancer treatment may include surgery, radiation, chemotherapy, hormone therapy, targeted therapy or immunotherapy. These approaches are not suitable for everyone. NCI identifies pembrolizumab as the only immunotherapy drug approved to treat breast cancer in its treatment overview; whether it is relevant depends on the individual case and current clinical guidance.
Examples of recent, specific approvals
NCI’s research overview describes two dated FDA approvals: in 2024, inavolisib with fulvestrant and palbociclib for certain patients with advanced or metastatic hormone receptor-positive breast cancer with PI3K mutations; and in 2025, datopotamab deruxtecan for ER-positive metastatic breast cancer. These approvals concern defined groups, not breast cancer generally. Eligibility and treatment details should be checked against current FDA labeling and discussed with an oncology team.
Quick Recap
What should you ask your care team?
- Is my screening plan based on my personal and family history as well as breast density?
- Was my exam 2D mammography or DBT, and what follow-up is appropriate for my results?
- If I have a diagnosis, which tumor biomarkers were tested, and how do they affect the options being considered?
- Is an AI-enabled tool being used for my particular test or procedure, and what role does the clinician retain?
- What will my insurance cover? The FDA advises contacting the insurer about coverage and provides a ZIP-code-searchable directory of certified mammography facilities.
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
